Lymphangioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

GARD: ¹⁹ Lymphatic malformations or lymphangiomas are benign (non-cancerous) vascular lesions made of fluid-filled spaces (cysts) thought to occur due to abnormal development of the lymphatic system. In general, Lymphatic malformations are categorized into macrocystic, microcystic, or combined depending on the size of the cysts; they are also classified in superficial lesions known as lymphangioma circumscriptum, and more deep-seated lesions (cavernous lymphangioma and cystic hygroma). They are present at birth, although they may be discovered later in life. They are most commonly located in the neck and axilla, but they also occur in the mouth, arm, mediastinum, lung, leg, abdomen and viscera. Some may appear as a tiny blue or red spot while others are massive and affect an entire arm or leg. The signs and symptoms vary depending on the size and location of the mass; however, lymphangiomas can disfigure affected areas and disrupt the function of nearby organs or tissues. The exact underlying cause is unknown.

MalaCards based summary: Lymphangioma, also known as lymphatic malformation, is related to cystic lymphangioma and capillary lymphangioma. An important gene associated with Lymphangioma is CELSR1 (Cadherin EGF LAG Seven-Pass G-Type Receptor 1), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Sirolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, tongue and adrenal gland, and related phenotypes are Increased cell migration and homeostasis/metabolism

Disease Ontology: ¹¹ A benign vascular tumor that is composed of dilated lymphatic channels.

Wikipedia: ⁷⁵ Lymphangiomas are malformations of the lymphatic system characterized by lesions that are thin-walled... more...

Sources

Related Diseases for Lymphangioma

Diseases related to Lymphangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 766)

#	Related Disease	Score	Top Affiliating Genes
1	cystic lymphangioma	33.2	PROX1 PECAM1 PDPN FLT4 CD34
2	capillary lymphangioma	33.2	PROX1 PECAM1 PDPN LYVE1 FLT4 CD34
3	colonic lymphangioma	32.7	PECAM1 PDPN CD34
4	lymphangiectasis	31.5	VIM ACTC1
5	hemangioma	31.5	VIM VEGFC VEGFA PROX1 PECAM1 PDPN
6	hereditary lymphedema i	31.2	VEGFC PROX1 PDPN NRP2 LYVE1 FLT4
7	cavernous hemangioma	31.2	VEGFA PECAM1 KDR CD34
8	kaposi sarcoma	31.2	VEGFC VEGFA PECAM1 PDPN LYVE1 KDR
9	intussusception	31.2	VEGFA PECAM1 KDR CD34
10	sarcoma	31.1	VIM PIK3CA KDR FLT4 BRAF ACTC1
11	hydrocele	31.0	VEGFA PECAM1 FLT4
12	klippel-trenaunay-weber syndrome	31.0	VEGFA PROX1 PIK3CA PECAM1 FLT4
13	vascular cancer	31.0	VEGFA PECAM1 KDR FLT4 CD34
14	hemangioendothelioma	30.9	FLT4 CD34
15	spindle cell hemangioma	30.8	PROX1 PECAM1 CD34
16	angiosarcoma	30.8	VIM VEGFC VEGFA PECAM1 PDPN KDR
17	lymphangiosarcoma	30.8	VEGFA PROX1 PECAM1 PDPN LYVE1 FLT4
18	gorham's disease	30.8	VEGFC VEGFA PROX1 PIK3CA PECAM1 PDPN
19	lipomatosis, multiple	30.8	PIK3CA PECAM1 CD34
20	primary lymphedema	30.7	VEGFC FLT4 CELSR1
21	arteriovenous malformation	30.7	VEGFA PECAM1 KDR CD34 BRAF
22	pancreatic cancer	30.7	VIM VEGFC VEGFA PIK3CA PECAM1 MIR143
23	congenital lymphedema	30.7	VEGFC PDPN FLT4
24	gallbladder disease	30.7	VEGFA PDPN MIR143 EGFR
25	capillary hemangioma	30.6	VEGFA PROX1 PECAM1 KDR FLT4 CD34
26	lymphangioleiomyomatosis	30.6	VEGFC VEGFA PDPN EGFR
27	cystadenocarcinoma	30.6	VIM VEGFC VEGFA PDPN AREG ACTC1
28	pneumothorax	30.6	VIM KDR ACTC1
29	hereditary lymphedema	30.6	VEGFC PROX1 PIK3CA PDPN NRP2 LYVE1
30	glomus tumor	30.5	VIM CD34 ACTC1
31	rhabdomyosarcoma	30.5	VIM VEGFA PIK3CA KDR EGFR ACTC1
32	lymphangitis	30.5	VEGFC PDPN LYVE1 FLT4 EGFR
33	hobnail hemangioma	30.5	PECAM1 PDPN FLT4 CD34
34	leiomyosarcoma	30.5	VIM VEGFA PECAM1 ACTC1
35	angiokeratoma circumscriptum	30.5	VEGFA PECAM1 KDR CD34
36	arteriovenous malformations of the brain	30.5	VEGFA PECAM1 KDR EGFR BRAF
37	liposarcoma	30.5	VIM VEGFA PIK3CA CD34
38	neurofibroma	30.4	VIM VEGFA PDPN EGFR CD34 ACTC1
39	adenocarcinoma	30.4	VEGFC VEGFA PIK3CA KDR FLT4 EGFR
40	rapidly involuting congenital hemangioma	30.4	PECAM1 FLT4
41	fibrosarcoma	30.4	VIM KDR EGFR ACTC1
42	neurilemmoma	30.4	VIM CD34 ACTC1
43	rectum adenocarcinoma	30.4	PIK3CA MIR143 EGFR
44	pyogenic granuloma	30.4	VEGFA PECAM1 LYVE1 FLT4 CD34 ACTC1
45	bladder cancer	30.3	VEGFC VEGFA PIK3CA MIR143 KDR EGFR
46	chylothorax, congenital	30.3	VEGFC FLT4
47	endometrial cancer	30.3	VEGFC VEGFA PIK3CA KDR EGFR BRAF
48	breast cancer	30.3	VIM VEGFC VEGFA PIK3CA PECAM1 PDPN
49	skin disease	30.3	VEGFA PIK3CA PECAM1 MIR18A IFNG EGFR
50	inflammatory breast carcinoma	30.3	VEGFC PROX1 LYVE1 EGFR

Comorbidity relations with Lymphangioma via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Lymphangioma:

Sources

Symptoms & Phenotypes for Lymphangioma

GenomeRNAi Phenotypes related to Lymphangioma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell migration	GR00055-A-1	9.23	KDR VEGFC
2	Increased cell migration	GR00055-A-3	9.23	KDR VEGFC

MGI Mouse Phenotypes related to Lymphangioma:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.47	ACTC1 AREG BRAF CD34 EGFR FLT4
2	muscle	MP:0005369	10.37	ACTC1 BRAF EGFR FLT4 IFNG KDR
3	cardiovascular system	MP:0005385	10.36	ACTC1 AREG BRAF EGFR FLT4 IFNG
4	growth/size/body region	MP:0005378	10.34	ACTC1 AREG BRAF CELSR1 EGFR FLT4
5	immune system	MP:0005387	10.33	AREG BRAF CD34 CELSR1 EGFR FLT4
6	cellular	MP:0005384	10.3	ACTC1 BRAF CD34 CELSR1 EGFR IFNG
7	normal	MP:0002873	10.27	ACTC1 BRAF EGFR FLT4 IFNG KDR
8	embryo	MP:0005380	10.21	BRAF CELSR1 EGFR FLT4 IFNG KDR
9	digestive/alimentary	MP:0005381	10.19	AREG BRAF EGFR FLT4 IFNG PDPN
10	liver/biliary system	MP:0005370	10.15	BRAF EGFR FLT4 IFNG KDR PECAM1
11	no phenotypic analysis	MP:0003012	10.11	EGFR FLT4 IFNG KDR NRP2 PIK3CA
12	respiratory system	MP:0005388	10.11	BRAF CELSR1 EGFR IFNG KDR NRP2
13	craniofacial	MP:0005382	10.02	BRAF CELSR1 EGFR IFNG KDR NRP2
14	reproductive system	MP:0005389	10.02	AREG BRAF CELSR1 EGFR FLT4 IFNG
15	vision/eye	MP:0005391	10	AREG BRAF CELSR1 EGFR IFNG KDR
16	hematopoietic system	MP:0005397	10	ACTC1 AREG BRAF CD34 CELSR1 EGFR
17	mortality/aging	MP:0010768	9.83	ACTC1 AREG BRAF CELSR1 EGFR FLT4
18	integument	MP:0010771	9.4	AREG BRAF CD34 CELSR1 EGFR FLT4

Sources

Drugs & Therapeutics for Lymphangioma

Drugs for Lymphangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

2

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

3

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

4

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

5

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

6

Anti-Bacterial Agents

Phase 4

7

Anti-Infective Agents

Phase 4

8

Antifungal Agents

Phase 4

9

Antibiotics, Antitubercular

Phase 4

10

Immunosuppressive Agents

Phase 4

11

Immunologic Factors

Phase 4

12

Picibanil

Phase 2, Phase 3

13

Sodium citrate

Approved, Investigational

Phase 1, Phase 2

68-04-2

23431961

14

Sildenafil

Approved, Investigational

Phase 1, Phase 2

139755-83-2, 171599-83-0

5212 135398744

15

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

77-92-9

311

16

Phosphodiesterase Inhibitors

Phase 1, Phase 2

17

Phosphodiesterase 5 Inhibitors

Phase 1, Phase 2

18

Vasodilator Agents

Phase 1, Phase 2

19

Citrate

Phase 1, Phase 2

20

Selenium

Approved, Investigational, Vet_approved

Phase 1

7783-07-5, 7782-49-2

533

21

Trace Elements

Phase 1

22

Antioxidants

Phase 1

23

Micronutrients

Phase 1

24

Protective Agents

Phase 1

Interventional clinical trials:

(show all 21)

#	Name	Status	NCT ID	Phase	Drugs
1	Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled Trial	Recruiting	NCT04921722	Phase 4	Percutaneous sirolimus;Oral sirolimus
2	Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial	Completed	NCT00010452	Phase 2, Phase 3	picibanil
3	A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies	Unknown status	NCT00975819	Phase 2	sirolimus
4	An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations	Completed	NCT01290484	Phase 1, Phase 2	Sildenafil
5	A Phase 2, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of OK-432 Immunotherapy in Individuals With Lymphatic Malformations	Completed	NCT03427619	Phase 2	OK432
6	Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations	Completed	NCT02335242	Phase 2	Sildenafil 20 mg tablets
7	TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN	Recruiting	NCT04128722	Phase 2	Sirolimus Oral Liquid Product 1mg/mL
8	A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations	Recruiting	NCT05050149	Phase 2	PTX-022
9	Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis	Recruiting	NCT03243019	Phase 2	rapamycin
10	Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations	Recruiting	NCT04861064	Phase 2	Sirolimus
11	0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical Trial	Recruiting	NCT03972592	Phase 2	Topical 0.1% Sirolimus;Topical Vehicle
12	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Terminated	NCT04409145	Phase 1, Phase 2	VT30
13	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc.	Recruiting	NCT04273334	Phase 1	68Ga-NEB
14	Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults	Terminated	NCT01212965	Phase 1	Selenium
15	A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations	Withdrawn	NCT04994002	Phase 1	CERC-006
16	Airway Vascular Lesions	Completed	NCT00866827
17	Diagnosis of Hemangiomas and Vascular Malformations Using Non-invasive Imaging Devices	Completed	NCT00577213
18	Validation of Core Biopsy of Vascular Anomalies for Clinical Pathology and Genomics	Completed	NCT04836884
19	Lymphatic Anomalies Registry for the Assessment of Outcome Data	Recruiting	NCT02399527
20	INST UNM 1601: Compassionate Use of BYL 719 Alpelisib	Available	NCT03941782		Alpelisib
21	Evaluation Nationale Des Enfants et Adultes Avec Syndromes d'Hypercroissance Dysharmonieuse National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)	Not yet recruiting	NCT05563831

Search NIH Clinical Center for Lymphangioma

Cochrane evidence based reviews: lymphangioma

Sources

Genetic Tests for Lymphangioma

Genetic tests related to Lymphangioma:

#	Genetic test	Affiliating Genes
1	Lymphangioma ²⁸
2	Lymphatic Malformation ²⁸

Sources

Anatomical Context for Lymphangioma

Organs/tissues related to Lymphangioma:

MalaCards : Lung, Tongue, Adrenal Gland, Small Intestine, Pancreas, Spleen, Colon

Sources

Publications for Lymphangioma

Articles related to Lymphangioma:

(show top 50) (show all 5774)

#	Title	Authors	PMID	Year
1	Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. ⁶² ⁵	Zenner K...Bennett JT	31536475	2019
2	PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. ⁶² ⁵	Blesinger H...Becker J	29985963	2018
3	Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. ⁶² ⁵	Luks VL...Murillo R	25681199	2015
4	PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. ⁵	Mirzaa G...Dobyns WB	27631024	2016
5	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. ⁵	Lee JW...Lee SH	15608678	2005
6	VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? ⁵³ ⁶²	Itakura E...Tsuneyoshi M	19151999	2009
7	Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. ⁵³ ⁶²	Norgall S...Weich HA	17584927	2007
8	Podoplanin: a novel diagnostic immunohistochemical marker. ⁵³ ⁶²	Ordonez NG	16670463	2006
9	Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. ⁵³ ⁶²	Xu H...Athanasou NA	15257549	2004
10	CD9 expression on lymphatic vessels in head and neck mucosa. ⁵³ ⁶²	Erovic BM...Pammer J	14559986	2003
11	The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. ⁵³ ⁶²	Wilting J...Rossler J	12060670	2002
12	Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. ⁵³ ⁶²	Huang HY...Hsu SM	11742043	2001
13	Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). ⁵³ ⁶²	Cursiefen C...Holbach LM	11585321	2001
14	Lymphangioma of large intestine: report of ten cases with endoscopic and pathologic correlation. ⁵³ ⁶²	Kim KM...Kim BK	10922105	2000
15	Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. ⁵³ ⁶²	Sinzelle E...Bruneval P	10931742	2000
16	Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. ⁵³ ⁶²	Folpe AL...Weiss SW	10697276	2000
17	Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. ⁵³ ⁶²	Partanen TA...Miettinen M	10590384	1999
18	Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. ⁵³ ⁶²	Sauter B...Rappersberger K	9446823	1998
19	Mesentric lymphatic malformation presented with a small bowel internal hernia: A case report. ⁶²	Rajeh A...Al Shaalan H	36340227	2023
20	A fetus with large mediastinal cystic lymphatic malformation managed with prenatal serial thoracocentesis and postnatal sclerotherapy. ⁶²	Muromoto J...Sago H	36164802	2022
21	Lymphatic/Blood Vessel Plasticity: Motivation for a Future Research Area Based on Present and Past Observations. ⁶²	Lampejo AO...Murfee WL	36459445	2022
22	Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations. ⁶²	Nozawa A...Ozeki M	36171295	2022
23	Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome. ⁶²	Carli D...Mussa A	35999193	2022
24	Hyperphosphatemic familial tumoral calcinosis mimicking a cystic hemo-lymphangioma on MRI. ⁶²	Houss SE...Lamalmi N	36193273	2022
25	Perinatal presentations of non-immune hydrops fetalis due to recessive PIEZO1 disease: a challenging fetal diagnosis. ⁶²	Ghesh L...Beneteau C	36453701	2022
26	Diagnosis of splenic cavernous lymphangioma by CT and multimodal MRI: a comparative analysis of imaging and pathology. ⁶²	Lan JY...Huang WB	36468694	2022
27	Right Ventricular Epicardium-Originated Cardiac Lymphangioma: A Rare Tumor and Rare Origin. ⁶²	Cora AR...Celik E	35216993	2022
28	Trifoliate mesenteric lymphatic malformation. ⁶²	Parida L	35840486	2022
29	The VASCERN-VASCA working group diagnostic and management pathways for lymphatic malformations. ⁶²	Ghaffarpour N...Vikkula M	36223836	2022
30	Institutional Management of Abdominal Lymphatic Malformations: Evolution of Treatment Over a Decade. ⁶²	Mehl SC...Rialon KL	36030605	2022
31	Paediatric lymphoedema: An audit of patients seen by the paediatric and primary lymphoedema group of vascular European Reference Network (VASCERN). ⁶²	Devoogdt N...Keeley V	36243335	2022
32	Lymphatic malformations in children: retrospective review of surgical and interventional management. ⁶²	Poget M...de Buys Roessingh A	36469112	2022
33	Long-term outcomes of lymphatic malformations in children: An 11-year experience from a tertiary referral center. ⁶²	Hyvonen H...Kyrklund K	35973860	2022
34	Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth. ⁶²	Wenger TL...Perkins JA	36066547	2022
35	Primary targeted medical therapy for management of bilateral head and neck lymphatic malformations in infants. ⁶²	Richardson CM...Perkins JA	36459725	2022
36	Extremely Rare Case of Cavernous Haemangioma of Submandibular Gland. ⁶²	Kalra R...Nayak P	36474490	2022
37	Curettage and sclerotherapy technique: A hybrid approach to superficial lymphatic malformation. ⁶²	Wang H...Guo Z	36444750	2022
38	Sirolimus-induced pulmonary hemorrhage of an infant with massive cervicofacial lymphatic malformation: A case report. ⁶²	Arya P...Evans S	36469963	2022
39	Condyloma acuminata mimicking cutaneous microcystic lymphatic malformation. ⁶²	Gomez-Arias PJ...Salido-Vallejo R	33666056	2022
40	Treatment With Topical Sirolimus for Recurrent Lymphatic Malformation of the External Urethral Meatus. ⁶²	Yonekura S...Kabashima K	36044195	2022
41	A lymphatic malformation with a "Lympholith" and encasing neurovascular structures in the arm of a 2-year-old child: A case report. ⁶²	Sharma S...Shrestha JM	36415720	2022
42	Fetal Cervical Lymphangioma: Magnetic Resonance Imaging and Three-Dimensional Reconstruction Modelling. ⁶²	Werner H...Araujo Junior E	34308843	2022
43	Rare finding of duodenal lymphangioma in a patient with Helicobacter pylori associated gastritis: A case report. ⁶²	Waheed S...Yousaf Z	36451462	2022
44	Mesenteric ruptured lymphangioma mimicking acute appendicitis. ⁶²	Wen TC...Lin KH	36427220	2022
45	Review of diagnosis, differential diagnosis, and management of retroperitoneal lymphangioma. ⁶²	Hoang VT...Hoang DT	36327088	2022
46	A Rare Case of Cystic Lymphangioma Involving the Fallopian Tube. ⁶²	Kim JH...Kim G	35908597	2022
47	Nevus Lipomatosus Superficialis in a Serous Inflammatory Capsule: A Case Report. ⁶²	Arasheben A...Barr S	36352757	2022
48	Microcystic lymphatic malformation presenting as firm, skin-colored papules of the lips. ⁶²	Edminister JR...Shwayder T	35739629	2022
49	[Incidental finding of a Müllerian cyst in an exceptional retroperitoneal localization]. ⁶²	Linard C...Rousselot P	35314077	2022
50	Laparoscopy ıs a defınıtıve dıagnostıc method for auto-amputated ovary ın ınfants. ⁶²	Parlak A...Dogruyol H	35964259	2022

Sources

Genes for Lymphangioma

Genes related to Lymphangioma (3 elite genes):

(show top 50) (show all 70)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CELSR1	Cadherin EGF LAG Seven-Pass G-Type Receptor 1	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	413.23	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	15608678 27631024 31536475 (more) 25681199 29985963
3	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	404.06	Pathogenic ⁵ DISEASES inferred ¹⁴
4	PDPN	Podoplanin	Protein Coding	23.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14559986 10931742 16670463 (more) 11585321 17584927
5	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	22.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19151999 11742043 17584927 (more) 12060670 10697276 11585321 10590384
6	VEGFC	Vascular Endothelial Growth Factor C	Protein Coding	18.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19151999 11742043
7	PROX1	Prospero Homeobox 1	Protein Coding	14.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12060670 17584927
8	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	13.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	EGFR	Epidermal Growth Factor Receptor	Protein Coding	13.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	KDR	Kinase Insert Domain Receptor	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	LYVE1	Lymphatic Vessel Endothelial Hyaluronan Receptor 1	Protein Coding	12.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15257549 17584927
12	AREG	Amphiregulin	Protein Coding	12.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	IFNG	Interferon Gamma	Protein Coding	11.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	NRP2	Neuropilin 2	Protein Coding	11.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	VIM	Vimentin	Protein Coding	11.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	9.89	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10922105
17	CD34	CD34 Molecule	Protein Coding	9.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12060670
18	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	9.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9446823
19	MIR18A	MicroRNA 18a	RNA Gene	8.08	DISEASES inferred ¹⁴ ¹⁴
20	MIR143	MicroRNA 143	RNA Gene	7.9	DISEASES inferred ¹⁴ ¹⁴
21	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.34	DISEASES inferred ¹⁴ ¹⁴
22	SERPINF1	Serpin Family F Member 1	Protein Coding	7.28	GeneCards inferred via : Publications (show sections)
23	CTNNB1	Catenin Beta 1	Protein Coding	7.28	DISEASES inferred ¹⁴
24	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	7.17	DISEASES inferred ¹⁴
25	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.95	DISEASES inferred ¹⁴
26	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.91	DISEASES inferred ¹⁴
27	SERPINA3	Serpin Family A Member 3	Protein Coding	6.87	DISEASES inferred ¹⁴ ¹⁴
28	TP53	Tumor Protein P53	Protein Coding	6.73	DISEASES inferred ¹⁴
29	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.7	DISEASES inferred ¹⁴
30	CDX2	Caudal Type Homeobox 2	Protein Coding	6.59	DISEASES inferred ¹⁴
31	MIR200A	MicroRNA 200a	RNA Gene	6.58	DISEASES inferred ¹⁴ ¹⁴
32	LGR5	Leucine Rich Repeat Containing G Protein-Coupled Receptor 5	Protein Coding	6.56	DISEASES inferred ¹⁴
33	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	6.54	DISEASES inferred ¹⁴
34	MIR15A	MicroRNA 15a	RNA Gene	6.44	DISEASES inferred ¹⁴ ¹⁴
35	MLH1	MutL Homolog 1	Protein Coding	6.42	DISEASES inferred ¹⁴
36	MIR199A1	MicroRNA 199a-1	RNA Gene	6.4	DISEASES inferred ¹⁴ ¹⁴
37	CCND1	Cyclin D1	Protein Coding	6.3	DISEASES inferred ¹⁴
38	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	6.27	DISEASES inferred ¹⁴
39	IL6	Interleukin 6	Protein Coding	6.27	DISEASES inferred ¹⁴
40	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.26	DISEASES inferred ¹⁴
41	MSH2	MutS Homolog 2	Protein Coding	6.13	DISEASES inferred ¹⁴
42	CDH1	Cadherin 1	Protein Coding	6.09	DISEASES inferred ¹⁴
43	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	6.04	DISEASES inferred ¹⁴ ¹⁴
44	MSH6	MutS Homolog 6	Protein Coding	6.01	DISEASES inferred ¹⁴
45	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.01	DISEASES inferred ¹⁴
46	CALB2	Calbindin 2	Protein Coding	5.99	DISEASES inferred ¹⁴
47	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	5.98	DISEASES inferred ¹⁴
48	IL17A	Interleukin 17A	Protein Coding	5.98	DISEASES inferred ¹⁴
49	H2AC18	H2A Clustered Histone 18	Protein Coding	5.95	DISEASES inferred ¹⁴ ¹⁴
50	TNF	Tumor Necrosis Factor	Protein Coding	5.93	DISEASES inferred ¹⁴

Sources

Variations for Lymphangioma

ClinVar genetic disease variations for Lymphangioma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	PIK3CA	NM_006218.4(PIK3CA):c.3202_3205delinsCTGATAACTGAGAAAATAACTGATAAAATGAAACTGA (p.Asn1068_Ter1069delinsLeuIleThrGluLysIleThrAspLysMetLysLeuArg)	INDEL	Pathogenic	1177432		GRCh37: 3:178952147-178952150 GRCh38: 3:179234359-179234362
2	CELSR1	NM_001378328.1(CELSR1):c.5226+2T>A	SNV	Pathogenic	598932	rs1569141899	GRCh37: 22:46804891-46804891 GRCh38: 22:46408994-46408994
3	CELSR1	NM_001378328.1(CELSR1):c.6739+1G>A	SNV	Pathogenic	598933	rs1569124017	GRCh37: 22:46782298-46782298 GRCh38: 22:46386401-46386401
4	BRAF	NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)	SNV	Pathogenic	13961	rs113488022	GRCh37: 7:140453136-140453136 GRCh38: 7:140753336-140753336
5	CELSR1	NM_001378328.1(CELSR1):c.868G>T (p.Glu290Ter)	SNV	Likely Pathogenic	590904	rs1569227576	GRCh37: 22:46932200-46932200 GRCh38: 22:46536303-46536303
6	CELSR1	NM_001378328.1(CELSR1):c.5702-1G>C	SNV	Likely Pathogenic	598923	rs1569133268	GRCh37: 22:46792644-46792644 GRCh38: 22:46396747-46396747
7	CELSR1	NM_001378328.1(CELSR1):c.2042del (p.Asn681fs)	DEL	Likely Pathogenic	598924	rs1569226110	GRCh37: 22:46931026-46931026 GRCh38: 22:46535129-46535129

Sources

Expression for Lymphangioma

Search GEO for disease gene expression data for Lymphangioma.

Sources

Pathways for Lymphangioma

Pathways related to Lymphangioma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	VIM VEGFC VEGFA NRP2 KDR FLT4
2	Signal Transduction ⁶⁶	13.73	VIM VEGFC VEGFA PIK3CA NRP2 KDR
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.7	VEGFC VEGFA NRP2 KDR FLT4 EGFR
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.53	VEGFC VEGFA PIK3CA KDR IFNG FLT4
5	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.24	VIM VEGFC VEGFA KDR FLT4 EGFR
6	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.06	VEGFC NRP2 KDR FLT4 EGFR AREG
7	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.04	VEGFC NRP2 KDR FLT4 EGFR BRAF
8	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.95	VEGFC VEGFA PIK3CA KDR FLT4 EGFR
9	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.71	BRAF EGFR KDR PIK3CA VEGFA
10	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.71	AREG EGFR FLT4 KDR VEGFC
11	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.54	VEGFC PIK3CA NRP2 KDR IFNG FLT4
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.5	PIK3CA EGFR BRAF AREG
13	Malignant pleural mesothelioma ⁷⁴	12.47	VEGFC VEGFA PIK3CA KDR FLT4 EGFR
14	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.45	PIK3CA FLT4 EGFR BRAF
15	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	EGFR FLT4 KDR PIK3CA
16	RhoGDI Pathway ⁶⁴ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶⁴	12.4	VEGFC VEGFA KDR FLT4 EGFR
17	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.38	VEGFA PIK3CA NRP2 KDR BRAF
18	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.34	VEGFC VEGFA PIK3CA NRP2 KDR FLT4
19	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.33	VEGFC VEGFA PIK3CA NRP2 KDR FLT4
20	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.32	AREG BRAF EGFR FLT4 KDR PIK3CA
21	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.27	VEGFC VEGFA PIK3CA NRP2 KDR FLT4
22	Ras signaling ⁷⁴	12.25	PIK3CA KDR FLT4 EGFR
23	Focal adhesion ⁷⁴	12.23	VEGFC VEGFA PIK3CA KDR EGFR BRAF
24	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.22	PIK3CA KDR FLT4 EGFR BRAF
25	Colorectal Cancer Metastasis ⁶⁴	12.19	VEGFA IFNG EGFR BRAF
26	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.19	VEGFC VEGFA KDR EGFR AREG
27	Tyrosine Kinases / Adaptors ³	12.14	VEGFC KDR FLT4 EGFR
28	mTOR Signaling ⁶⁵	12.1	KDR FLT4 EGFR BRAF
29	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	12.08	VIM VEGFA PROX1 KDR
30	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.89	PIK3CA EGFR AREG
31	CCL18 signaling pathway ⁷⁴	11.88	VIM VEGFC VEGFA
32	Allograft rejection ⁷⁴	11.86	VIM VEGFA IFNG
33	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.85	KDR FLT4 EGFR
34	Clear cell renal cell carcinoma pathways ⁷⁴	11.82	VEGFA KDR EGFR
35	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.78	BRAF FLT4 KDR PIK3CA
36	Head and neck squamous cell carcinoma ⁷⁴	11.74	VEGFA PIK3CA EGFR
37	Signaling events mediated by VEGFR1 and VEGFR2 ⁶¹	11.67	VEGFA PIK3CA KDR BRAF
38	Integrins in angiogenesis ⁶¹	11.63	VEGFA PIK3CA KDR
39	Hair follicle development: cytodifferentiation - part 3 of 3 ⁷⁴	11.6	IFNG EGFR CD34
40	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.57	VEGFA PECAM1 KDR EGFR
41	Cell adhesion_Plasmin signaling ²²	11.55	VEGFA PIK3CA KDR
42	Heart development ⁷⁴	11.52	VEGFC VEGFA MIR143
43	Signaling events mediated by TCPTP ⁶¹ Show member pathways MET activates PI3K/AKT signaling ⁶⁶	11.48	VEGFA PIK3CA KDR EGFR
44	SHP2 signaling ⁶¹	11.45	VEGFA PIK3CA KDR IFNG EGFR
45	Bladder cancer ⁷⁴	11.44	BRAF EGFR VEGFA
46	Beta3 integrin cell surface interactions ⁶¹	11.43	VEGFA PECAM1 KDR
47	G-protein signaling_K-RAS regulation pathway ²²	11.24	BRAF EGFR PIK3CA
48	Immune infiltration in pancreatic cancer ⁷⁴	11.24	IFNG VEGFA VEGFC
49	VEGFR1 specific signals ⁶¹	11.2	VEGFA PIK3CA NRP2
50	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.19	VEGFA KDR FLT4 EGFR BRAF

Sources

GO Terms for Lymphangioma

Cellular components related to Lymphangioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.7	PECAM1 PDPN NRP2 LYVE1 KDR FLT4
2	plasma membrane	GO:0005887	9.7	PECAM1 PDPN NRP2 LYVE1 KDR FLT4

Biological processes related to Lymphangioma according to GeneCards Suite gene sharing:

(show all 36)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.41	VIM VEGFA IFNG CD34 BRAF ACTC1
2	negative regulation of apoptotic process	GO:0043066	10.41	VEGFA PDPN KDR FLT4 EGFR BRAF
3	negative regulation of gene expression	GO:0010629	10.36	VEGFA PIK3CA KDR IFNG CD34
4	positive regulation of cell population proliferation	GO:0008284	10.36	VEGFC VEGFA PROX1 KDR IFNG FLT4
5	angiogenesis	GO:0001525	10.28	VEGFC VEGFA PIK3CA NRP2 KDR FLT4
6	cell-cell adhesion	GO:0098609	10.27	PECAM1 PDPN EGFR CELSR1 CD34
7	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.26	VEGFA KDR FLT4 EGFR BRAF
8	peptidyl-tyrosine phosphorylation	GO:0018108	10.21	KDR FLT4 EGFR BRAF
9	positive regulation of angiogenesis	GO:0045766	10.2	CD34 KDR MIR143 VEGFA VEGFC
10	positive regulation of peptidyl-serine phosphorylation	GO:0033138	10.19	BRAF EGFR PIK3CA VEGFA
11	lung development	GO:0030324	10.14	VEGFA PROX1 PDPN KDR
12	positive regulation of cell migration	GO:0030335	10.13	VEGFC VEGFA PECAM1 PDPN KDR FLT4
13	positive regulation of protein kinase B signaling	GO:0051897	10.11	VEGFA PIK3CA MIR143 EGFR
14	epidermal growth factor receptor signaling pathway	GO:0007173	10.11	PIK3CA EGFR BRAF AREG
15	sprouting angiogenesis	GO:0002040	10.1	VEGFC VEGFA FLT4
16	cellular response to vascular endothelial growth factor stimulus	GO:0035924	10.09	VEGFA KDR FLT4
17	positive regulation of endothelial cell migration	GO:0010595	10.07	VEGFA PROX1 NRP2 KDR FLT4
18	positive regulation of protein phosphorylation	GO:0001934	10.07	BRAF EGFR FLT4 KDR PECAM1 VEGFA
19	positive regulation of epithelial cell proliferation	GO:0050679	10.03	VEGFC VEGFA KDR EGFR
20	positive regulation of blood vessel endothelial cell migration	GO:0043536	10.02	VEGFC VEGFA MIR143 KDR
21	vascular endothelial growth factor receptor signaling pathway	GO:0048010	10.01	FLT4 KDR VEGFA VEGFC
22	lymphangiogenesis	GO:0001946	10	PROX1 PDPN FLT4
23	skeletal muscle thin filament assembly	GO:0030240	9.96	ACTC1 PROX1
24	positive regulation of mast cell chemotaxis	GO:0060754	9.96	VEGFA VEGFC
25	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	9.95	VEGFA KDR
26	vascular endothelial growth factor receptor-2 signaling pathway	GO:0036324	9.94	VEGFA KDR
27	glomerular endothelium development	GO:0072011	9.93	PECAM1 CD34
28	positive regulation of endothelial cell proliferation	GO:0001938	9.93	VEGFC VEGFA PROX1 NRP2 KDR FLT4
29	blood vessel endothelial cell differentiation	GO:0060837	9.92	KDR PROX1
30	vascular wound healing	GO:0061042	9.91	VEGFA KDR CD34
31	lymphatic endothelial cell fate commitment	GO:0060838	9.9	PROX1 PDPN
32	lymph vessel development	GO:0001945	9.89	FLT4 KDR PROX1
33	aorta smooth muscle tissue morphogenesis	GO:0060414	9.83	PROX1 MIR143
34	actin-mediated cell contraction	GO:0070252	9.79	ACTC1 PDPN
35	positive regulation of phosphorylation	GO:0042327	9.43	VEGFA KDR FLT4 EGFR AREG
36	vascular endothelial growth factor signaling pathway	GO:0038084	9.4	VEGFC VEGFA PIK3CA NRP2 KDR FLT4

Molecular functions related to Lymphangioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor binding	GO:0019838	9.63	NRP2 KDR FLT4
2	vascular endothelial growth factor receptor binding	GO:0005172	9.56	VEGFC VEGFA
3	protein tyrosine kinase activity	GO:0004713	9.43	KDR FLT4 EGFR BRAF
4	vascular endothelial growth factor receptor activity	GO:0005021	9.1	NRP2 KDR FLT4

Sources

Sources for Lymphangioma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: LYM022 MIFTS: 58	Lymphangioma Categories: Cancer diseases, Cardiovascular diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables